CSIMarket
 
Janux Therapeutics Inc   (JANX)
Other Ticker:  
 
 
Price: $9.9600 $0.53 5.620%
Day's High: $10.025 Week Perf: 25.6 %
Day's Low: $ 8.95 30 Day Perf: 7.68 %
Volume (M): 186 52 Wk High: $ 18.28
Volume (M$): $ 1,856 52 Wk Avg: $11.26
Open: $9.35 52 Wk Low: $5.65



 Market Capitalization (Millions $) 455
 Shares Outstanding (Millions) 46
 Employees -
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -63
 Cash Flow (TTM) (Millions $) -34
 Capital Exp. (TTM) (Millions $) 1

Janux Therapeutics Inc
Janux Therapeutics Inc is a privately held biotechnology company that focuses on developing next-generation cancer immunotherapies. The company was founded in 2017 and is headquartered in San Diego, California.

Janux Therapeutics is committed to advancing cancer immunotherapy through the development of innovative drug candidates. The company's pipeline includes both small molecule drugs and biologics that have the potential to activate the immune system to target and destroy cancer cells.

The company's lead candidate, JAN101, is a small molecule drug that targets the tumor microenvironment. JAN101 is designed to selectively activate immune cells within the tumor microenvironment, leading to tumor regression and improved patient outcomes. The drug has demonstrated promising preclinical results in a range of cancer models and is currently in Phase 1 clinical trials.

Janux Therapeutics' pipeline also includes a number of next-generation biologics that utilize the company's proprietary Tumor Activated T Cell Engager (TRACT) platform. TRACT molecules are designed to selectively target and activate T cells within the tumor microenvironment, leading to improved tumor killing and reduced toxicity compared to traditional T cell-engaging therapies. The company is currently advancing several TRACT molecules through preclinical development.

In addition to its drug development programs, Janux Therapeutics has established a number of partnerships with leading pharmaceutical companies. The company has partnered with Merck to develop novel cancer immunotherapies using Janux's TRACT technology.

Janux Therapeutics' team includes experienced biotech executives, renowned scientists, and drug developers with a proven track record in developing novel cancer therapies. The company is backed by top-tier venture capital firms, including Polaris Partners, Avalon Ventures, and Section 3


   Company Address: 10955 Vista Sorrento Parkway, Suite 200 San Diego 92130 CA
   Company Phone Number: 751-4493   Stock Exchange / Ticker: NASDAQ JANX
   JANX is expected to report next financial results on March 09, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Janux Therapeutics Inc

Janux Therapeutics Inc Soars to New Financial Heights, Demonstrating Remarkable Growth in Stock Market Performance


Date: September 30, 2023
Janux Therapeutics Inc, a leading company in the Major Pharmaceutical Preparations industry, has exhibited significant improvements in its financial performance and stock market position, according to the recently released financial report for the period ending September 30, 2023.
In terms of earnings per share (EPS), Janux Therapeutics Inc marked a positive financial development with a loss per share reduced to $-0.25 compared to $-0.40 in the same period last year. Furthermore, there was a notable improvement from the previous reporting period with EPS improving from $-0.42. The company's efforts to enhance profitability have delivered positive results.

Janux Therapeutics Inc

Janux Therapeutics Inc. Suffers Dramatic Plunge in Revenue During April to June 2023, Raising Concerns for Future

Janux Therapeutics Inc, the major pharmaceutical preparations company, recently reported a disastrous financial period ending June 30, 2023. The company's revenue plummeted by a staggering -55.307%, reaching only $1.06 million. Additionally, the shortfall per share has expanded to $-0.42, which marks a significant decline compared to the corresponding financial reporting period from the previous year. Moreover, the revenue tumbled sequentially by -48.389%, dropping from $2.05 million.
During the second quarter of 2023 earnings season, Janux Therapeutics Inc experienced a net loss of $-17.508 million, surpassing the $-16.888 million loss from the previous year. These alarming financial results have undoubtedly raised concerns among investors and stakeholders.

Janux Therapeutics Inc

Despite Strong Revenue Growth, Janux Therapeutics Inc Struggles to Achieve Profitability in Recent Fiscal Period

Janux Therapeutics Inc is a healthcare company that focuses on developing innovative cancer therapies using a new generation of small molecule immunotherapies. In their most recent fiscal period, the company announced a surge in revenue by 28.886% to $2.05 million from the comparable financial reporting period a year before, which is a positive development. However, the company has also seen an increase in its shortfall per share, which is now at $-0.42 per share.
A shortfall per share occurs when a company's operating costs exceed its revenue. This often happens when a company is in a growth phase or is investing heavily in research and development, as is the case with Janux Therapeutics Inc. In comparison to the preceding period, the company's shortfall has grown from $-0.38 per share, indicating that they may be investing more heavily in their operations than in the past.
In addition to the increase in shortfall per share, Janux Therapeutics Inc has also seen a decline in revenue, which fell by -28.014 % from $2.85 million in the preceding period. It is important to note that revenue can fluctuate based on a number of factors, including market conditions, competition, and new product releases.
For the most recent fiscal period, Janux Therapeutics Inc realized a net shortfall of $-17.459 million, which is bigger than its $-13.410 million shortfall a year ago. It is worth noting that these numbers are not unusual for a company at Janux Therapeutics Inc's stage of development, as they are still in the process of developing their product pipeline.






 

Janux Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com